

2 November 2017

NSX Announcement

## **BERONI SIGNS LETTER OF INTENT WITH UNSW**

Beroni Group Limited (“Beroni Group” or the “Company”) is pleased to announce that it has signed a letter of intent with Cystemix Pty Limited (“Cystemix”), an associated entity of the University of New South Wales, specialising in managing the scientific and commercialising the development of an anti-cancer drug called GSAO.

Pursuant to the letter of intent, Beroni was granted a four-month exclusive period to assess information and conduct due diligence on Cystemix and GSAO prior to it making a decision to invest in Cystemix. The investment (if any) is to fund the necessary clinical trials and commercialisation of GSAO. The terms of investment are to be negotiated by the parties during the exclusive period.

The Company will continue to inform shareholders of the progress of this potential investment into Cystemix.

For further information please contact:

Mr Jacky Zhang  
Executive Chairman  
Tel: +86 1851 6931 911  
E: [1710426553@qq.com](mailto:1710426553@qq.com)

Mr Peter Wong  
Non-Executive Director  
Tel: +61 423 727 580  
E: [pwong@asiainvest.com.au](mailto:pwong@asiainvest.com.au)

### **About Beroni Group Limited (NSX: BTG)**

Beroni Group’s currently has four main products: NicoBloc, Fogibloc, Multi Vigorous tablets (Bei Jingli) and Multi lung cleaning tablets (Bei Feiqing). Beroni Group’s overall strategic goal is to have a global presence in the biotechnology, bio-science and environmental science industries. The Company is open to acquisition opportunities to expand the business and increase its market share.